-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
89bio (NASDAQ:ETNB) Trading Down 5.2% Following Insider Selling
89bio (NASDAQ:ETNB) Trading Down 5.2% Following Insider Selling
89bio, Inc. (NASDAQ:ETNB – Get Rating) fell 5.2% on Friday following insider selling activity. The company traded as low as $11.58 and last traded at $11.58. 34,720 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,181,226 shares. The stock had previously closed at $12.21.
Specifically, CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the completion of the sale, the chief financial officer now directly owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Ryan Martins sold 5,947 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the sale, the chief financial officer now owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,172,741 shares of 89bio stock in a transaction that occurred on Tuesday, October 18th. The stock was bought at an average cost of $7.65 per share, for a total transaction of $8,971,468.65. Following the purchase, the director now owns 8,955,410 shares in the company, valued at approximately $68,508,886.50. The disclosure for this purchase can be found here. Company insiders own 11.80% of the company's stock.
Get 89bio alerts:Analyst Upgrades and Downgrades
Several equities research analysts have commented on ETNB shares. Royal Bank of Canada dropped their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a research note on Friday, November 11th. Raymond James raised their price objective on shares of 89bio from $14.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Wednesday, September 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a research note on Monday, November 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.25.
89bio Price Performance
The company's fifty day moving average is $9.69 and its two-hundred day moving average is $6.69. The firm has a market capitalization of $537.04 million, a price-to-earnings ratio of -2.65 and a beta of 0.89. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.08.Institutional Investors Weigh In On 89bio
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new position in shares of 89bio in the 3rd quarter valued at about $34,000. Acadian Asset Management LLC acquired a new stake in 89bio in the 1st quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter worth about $60,000. Rhumbline Advisers acquired a new stake in 89bio in the 1st quarter worth about $42,000. Finally, Mirabella Financial Services LLP acquired a new stake in 89bio in the 1st quarter worth about $43,000. 87.78% of the stock is currently owned by institutional investors and hedge funds.
About 89bio
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Further Reading
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
89bio, Inc. (NASDAQ:ETNB – Get Rating) fell 5.2% on Friday following insider selling activity. The company traded as low as $11.58 and last traded at $11.58. 34,720 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,181,226 shares. The stock had previously closed at $12.21.
受内幕抛售活动影响,新浪纳斯达克(Sequoia Capital:ETNB-GET)股价周五下跌5.2%。该公司股价低至11.58美元,最新报11.58美元。午盘成交量为34,720股,较1,181,226股的平均日成交量下降97%。该股此前收盘价为12.21美元。
Specifically, CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the completion of the sale, the chief financial officer now directly owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Ryan Martins sold 5,947 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the sale, the chief financial officer now owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,172,741 shares of 89bio stock in a transaction that occurred on Tuesday, October 18th. The stock was bought at an average cost of $7.65 per share, for a total transaction of $8,971,468.65. Following the purchase, the director now owns 8,955,410 shares in the company, valued at approximately $68,508,886.50. The disclosure for this purchase can be found here. Company insiders own 11.80% of the company's stock.
具体而言,首席财务官瑞安·马丁斯在日期为1月3日(星期二)的交易中出售了5,947股89Bio股票。该股以12.51美元的平均价格出售,总成交金额为74,396.97美元。出售完成后,首席财务官现在直接拥有该公司36,368股股票,价值约为454,963.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个环节。在其他新闻方面,首席财务官瑞安·马丁斯在1月3日星期二的一次交易中出售了5947股该公司的股票。该股以12.51美元的平均价格出售,总成交金额为74,396.97美元。出售后,首席财务官现在拥有该公司36,368股股票,价值约454,963.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。此外,董事Ra Capital Management,L.P.在10月18日(星期二)的一笔交易中购买了89Bio1,172,741股股票。这只股票的平均价格为每股7.65美元,总交易金额为8,971,468.65美元。收购完成后,董事现在拥有该公司8955,410股,价值约68,508,886.50美元。关于这次购买的披露可以找到这里。公司内部人士持有该公司11.80%的股份。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several equities research analysts have commented on ETNB shares. Royal Bank of Canada dropped their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a research note on Friday, November 11th. Raymond James raised their price objective on shares of 89bio from $14.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Wednesday, September 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a research note on Monday, November 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.25.
几位股票研究分析师对ETNB的股票发表了评论。11月11日,加拿大皇家银行在一份周五的研究报告中将89Bio的目标价从35.00美元下调至29.00美元,并对该股设定了“跑赢大盘”的评级。雷蒙德·詹姆斯在9月14日星期三的一份研究报告中将89Bio的股票目标价从14.00美元上调至25.00美元,并给出了该股“强势买入”的评级。最后,康托·菲茨杰拉德在11月14日(星期一)的一份研究报告中重申了对89Bio的增持评级,并发布了每股34.00美元的目标价(此前为27.00美元)。七位研究分析师对该股的评级为买入,一位分析师对该公司发出了强烈的买入评级。根据MarketBeat.com的数据,该股的平均评级为买入,共识目标价为25.25美元。
89bio Price Performance
89Bio性价比
Institutional Investors Weigh In On 89bio
机构投资者参与89Bio
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new position in shares of 89bio in the 3rd quarter valued at about $34,000. Acadian Asset Management LLC acquired a new stake in 89bio in the 1st quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter worth about $60,000. Rhumbline Advisers acquired a new stake in 89bio in the 1st quarter worth about $42,000. Finally, Mirabella Financial Services LLP acquired a new stake in 89bio in the 1st quarter worth about $43,000. 87.78% of the stock is currently owned by institutional investors and hedge funds.
对冲基金和其他机构投资者最近改变了他们在该股的头寸。Quantbot Technologies LP在第三季度购买了89Bio的新头寸,价值约3.4万美元。Acadian Asset Management LLC在第一季度收购了89Bio的新股份,价值约3.4万美元。CapTrust Financial Advisors在第三季度收购了89Bio价值约6万美元的新股份。Rhumbline Advisers在第一季度收购了89Bio的新股份,价值约4.2万美元。最后,Mirabella Financial Services LLP在第一季度收购了89Bio价值约43,000美元的新股份。87.78%的股票目前由机构投资者和对冲基金持有。
About 89bio
约89Bio
(Get Rating)
(获取评级)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
89BioInc.是一家临床阶段的生物制药公司,专注于治疗肝脏和心脏代谢性疾病的疗法的开发和商业化。它的主要候选产品是pegozafermin,一种用于治疗非酒精性脂肪性肝炎的成纤维细胞生长因子21的糖基化类似物。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
- 免费获取股票新闻网站89Bio(ETNB)上的研究报告
- MarketBeat:回顾中的一周01/02-01/06
- 为什么CrowdStrike的股价举步维艰?
- 2023年四只被低估的医疗保健股票
- WWE股票:文斯·麦克马洪想要重返节目
- NVIDIA正在触底,但现在还不能买入
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
接受89Bio日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对89Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧